Tech Company Inital Public Offerings
Stoke Therapeutics IPO
On 6/18/2019, Stoke Therapeutics became a public company.
Transaction Overview
Company Name
Announced On
6/18/2019
Transaction Type
IPO
Amount
$142,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: approximately $36.0 million to $39.0 million to advance our lead product candidate, STK-001, through initiation of a Phase 3 clinical trial; approximately $34.0 million to $37.0 million to nominate, conduct preclinical studies for and demonstrate clinical proof of concept for additional product candidates; and any remaining amounts to fund working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3 Preston Ct. 102
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Website
Email Address
Overview
Stoke (Nasdaq: STOK) is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Edward Kaye
Chief Medical Officer
Barry Ticho
Chief Operating Officer
Huw Nash
Vice President
Charles Allerson
Vice President
Isabel Aznarez
VP - R & D
Gene Liau
Browse more venture capital transactions:
Prev: 6/18/2019: IronScales venture capital transaction
Next: 6/18/2019: Quartet venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs